Absci (ABSI) Leerink Global Healthcare Conference 2026 summary

Platform overview and strategic focus

• AI-driven platform targets challenging drug targets like GPCRs and ion channels, aiming for differentiated assets.

• Origin-1 model enables design against zero prior epitopes, expanding pipeline potential.

• Early pipeline assets are positioned for future partnering opportunities.

• Internal pipeline includes ABS-201, focused on androgenetic alopecia (AGA) and endometriosis.

• Selective advancement of programs prioritizes ROI and market opportunity.

Androgenetic alopecia (AGA) program

• AGA affects 80 million in the US; current therapies lack efficacy, convenience, and adherence.

• ABS-201 offers a novel subcutaneous injection with potential for long-lasting hair growth and improved patient adherence.

• Mechanism targets peripheral prolactin, shown to drive hair miniaturization; blocking prolactin promotes hair growth and stem cell replenishment.

• Key endpoints include hair count and pigmentation restoration, with interim and final readouts at 13 and 26 weeks.

• Market research suggests a $25 billion TAM for AGA, with rapid trial recruitment and low development costs.

Endometriosis program

• Prolactin inhibition supported by animal and competitor data as a dual mechanism for lesion formation and pain.

• Phase II trial planned for Q4, focusing on pain reduction as the primary endpoint.

• Patient selection will emphasize baseline pain and accurate diagnosis, with trial design details forthcoming.

• Recent addition of a CMO with pain trial experience strengthens execution.

• Interim efficacy readout for endometriosis expected in the second half of 2027.